

This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma

World Journal of Surgical Oncology 2011, **9**:43 doi:10.1186/1477-7819-9-43

Zhouxun Chen (zhouxun.chen@googlemail.com)
Shuchen Gu (susanuse@googlemail.com)
Bogusz Trojanowicz (bogusz.trojanowicz@medizin.uni-halle.de)
Naxin Liu (lnx68@sina.com)
Guanbao Zhu (zgbwmc@yahoo.com.cn)
Henning Dralle (henning.dralle@medizin.uni-halle.de)
Cuong Hoang-Vu (hoang-vu@medizin.uni-halle.de)

ISSN 1477-7819

Article type Research

Submission date 25 April 2009

Acceptance date 27 April 2011

Publication date 27 April 2011

Article URL <http://www.wjso.com/content/9/1/43>

This peer-reviewed article was published immediately upon acceptance. It can be downloaded, printed and distributed freely for any purposes (see copyright notice below).

Articles in *WJSO* are listed in PubMed and archived at PubMed Central.

For information about publishing your research in *WJSO* or any BioMed Central journal, go to

<http://www.wjso.com/info/instructions/>

For information about other BioMed Central publications go to

<http://www.biomedcentral.com/>

© 2011 Chen *et al.*; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Title:

Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma

Running title:

TM4SF members in gastric carcinoma

Authorship:

Zhouxun Chen^{1,2}, Suchen Gu², Bogusz Trojanowicz², Naxin Liu¹, Guanbao Zhu¹, Henning Dralle²
and Cuong Hoang-Vu²

Institution:

¹Department of General Surgery, The first affiliated Hospital of Wenzhou medical School, Wenzhou 325000, Zhejiang, PR. China

²Department of General, Visceral and Vascular Surgery, Martin-Luther-University Halle-Wittenberg, Halle/ Saale 06097, Germany

Correspondence to:

Zhouxun Chen (MD, PhD)

Department of General Surgery, The first affiliated Hospital of Wenzhou medical school, Fuxue Road 2, Wenzhou 325000, Zhejiang, PR. China

E-mail: zhouxun.chen@googlemail.com

Telephone and fax:

Telephone: +86-577-8806 9307

Fax: +86-577-8806 9555

ABSTRACT

Background: The aim of this study was to clarify the clinical significance of TM4SF members CD9, CD63 and CD82 in human gastric carcinoma.

Methods: By employing RT-PCR and immunohistochemistry, we studied the expression of CD9, CD63 and CD82 in 49 paired tissue specimens of normal gastric mucosa and carcinoma. All tissues were obtained from patients who underwent curative surgery.

Results: All normal gastric epithelium and gastric ulcer tissues strongly expressed transcripts and proteins of CD9, CD63 and CD82 as compared with corresponding controls. We found a significant correlation between CD63 mRNA level and different pM statuses ($P=0.036$). Carcinomas in M0 stage revealed a stronger expression of CD63 than carcinomas in M1 stage. Expression of CD9 protein was found significantly stronger in pN0, pM0 than in advanced pN stages ($P=0.03$), pM1 ($P=0.013$), respectively. We found the relationship between CD63 expression, gender ($p=0.09$) and nodal status ($p=0.028$), respectively. Additionally, advanced and metastasized tumor tissues revealed significantly down-regulated CD82 protein expression ($p=0.033$ and $p=0$, respectively), which correlated with the tumor pTNM stage ($p=0.001$).

Conclusion: The reduction of CD9, CD63 and CD82 expression are indicators for the metastatic potential of gastric carcinoma cells. Unlike their expression in other tumor types, the constitutive expression of CD63 may indicate that this factor does play a direct role in human gastric carcinogenesis.

INTRODUCTION

The TM4 superfamily (TM4SF) includes more than 20 core members and a number of additional proteins with sequence similarities. Nearly all mammalian cells contain one or more TM4SF proteins. The correct biological functions of the TM4 superfamily could not have been fully elucidated, but it has been reported that several TM4SF members, such as CD9, CD63, CD81, CD82 and CD151 might be involved in cell signaling. Furthermore, recent data suggest some TM4SF members might play roles in signal transduction pathways and to regulate cell activation, development, proliferation, and motility [1]. For instance, CD9, CD82 and CD63 have been reported to modulate the tumor progression or metastasis[2,3,4]. As type III integral membrane glycoproteins, CD9, CD82 and CD63 have two divergent extracellular loop domains, the larger of which contains several conserved amino acid motifs, highly conserved hydrophobic tetra-transmembrane domains and two short cytoplasmic domains at the NH₂ and COOH termini[5,6].

CD9 gene is located on human chromosome 12p13.3 and encodes 227 amino acids. It was described originally as a 24-kDa surface protein of non-T acute lymphoblastic leukemia cells and developing B-lymphocytes[7]. CD9 is also expressed in plasma membrane of various cell types, including hematopoietic cells, endothelial cells, normal epithelial cells, and several tumor cell types[8-12]. Some clinical and experimental studies demonstrated that CD9 functions as a tumor metastatic suppressor in various cancers, including non-small-cell lung cancers, breast cancers, and colon cancers[13-15]. The CD82 gene is located on human chromosome 11p11.2 and encodes a 2.4 kb transcript which is translated into a N-glycosylated, transmembrane protein of 267 amino acids[3,16]. It attracted considerable attention as a tumor metastasis suppressor gene in prostatic cancer. Recent and retrospective studies have shown that decreased wild type CD82 expression could be a useful marker for metastatic and has invasive potential in some human tumor types, including pancreatic, breast, colorectal, bladder and oral cancers[17-23]. CD63 is isolated from human chromosome 12p12-q13 has been implicated in phagocytic and intracellular lysosome-phagosome fusion events. CD63 plays a role in the regulation of cell motility in melanoma cells and is involved in cell adhesion events[24], and strongly expressed on the cell surface in the early stage of malignant melanoma but weakly in the more advanced stages[25]. The data of our previous study demonstrated the expression of CD82 was correlated significantly with the metastatic status of human thyroid carcinoma. However, CD63 expression pattern did not correlate with any tumor staging[26].

The biological functions of these factors in human gastric carcinoma are still not clearly understood. In this retrospective study on staged human gastric carcinoma tissues, we investigated the expression of these three TM4SF members to determine whether they correlate with the invasiveness and metastatic ability of gastric carcinoma cells.

MATERIALS AND METHODS

Tissue specimens

No patient was required the perioperative neo/adjuvant chemotherapy in this study. From each patient, one representative primary tumor block, including tumor centre and invasion front as well as tumor-associated non-neoplastic mucosa, were examined by immuno-histochemistry.

Forty-nine patients were included in this study who with up to stage IV gastric carcinoma at the Department of General, Visceral and Vascular Surgery of Martin-Luther-University Halle-Wittenberg between 1994 and 2002. This study was approved by the local committee of medical ethics and all patients gave written consent. Tumor tissues were staged according to the Tumor-node-metastasis (TNM) staging classification (UICC-AJCC 1997). The clinical characteristics of the patients with gastric carcinoma are presented in Table 1.

For employing Semi quantitative RT-PCR and immunohistochemistry, resected gastric tissues were immediately frozen in liquid nitrogen and maintained at -80° C. Frozen sections at 6µm were cut by using Microm cryostat system (Microm International GmbH, Walldorf, Germany) on a cryostat and control sections were hematoxylin-eosin stained.

Semi quantitative RT-PCR

To prevent crosscontamination of samples and carry-over contamination, laser-assisted microdissection was performed for subsequent isolation of genomic RNA (P.A.L.M.® system, Bernried, Germany). Total RNA from fresh tissue samples, SW480 cell line (human colon carcinoma cell line) and FTC-133 (human follicular thyroid carcinoma cell line) was extracted by using the TRIZOL reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's protocol. First-strand cDNA synthesis was performed with 1µg of total RNA using a cDNA synthesis kit (Gibco, Munich, Germany) following the manufacturer's protocol at 42°C for 30 min followed by enzyme inactivation at 95°C for 5 min.

For PCR amplification, a 2µl aliquot of the reaction mixture was used. The following PCR primer pairs were used to amplify a 800bp amplicon of CD9 (sense 5' -TGCATCTGTATCCAGCGCCA-3'/ antisense 5' -CTCAGGGATGTAAGCTGACT-3'); a 598bp encoding CD82 (sense 5'- GCA GTC ACT ATG CTC ATG G -3'/ antisense 5'- TGC TGT AGT CTT CGG AAT G -3') and a 347bp amplicon for CD63 (sense 5'- CCC GAA AAA CAA CCA CAC TGC -3'/ antisense 5'- GAT GAG GAG GCT GAG GAG ACC -3'), and a 467bp amplicons for the housekeeping genes GAPDH (sense 5'- TGG TGA AGG TCG GTG TGA AC -3'/ antisense 5'- TTC CCA TTC TCA GCC TTG AC -3'). All PCR reactions were performed with AmpliTaq (for CD9, CD82 and 18S) and AmpliTaq-Gold (for CD63) (Amersham, USA). The PCR profile was as follows: 30 sec at 94°C, 45 sec at (CD9: 60°C; CD82:58°C; CD63:56°C, GAPDH:60°C) and 30 sec at 72°C. CD9, CD82, CD63 and GAPDH consisted of 30 sec at 94°C, 30 sec at 60°C, 45 sec at 72°C, and a final elongation step for 7min at

72°C. 20µl PCR products were run visualized in a 1.5% agarose gel (PeqLab), photographed with Kodak Image System 440cf and electronically evaluated with “TL100” Total Lab software (Nonlinear Dynamics, UK). The expression of positive control was set as 100% (Figure 1), the expression levels of all investigated specimens were classified in comparison to the positive controls (for CD9 and CD63: SW480; and for CD82: FTC-133-CD82 overexpressing clone) grey scale. The densitometric values obtained for CD9, CD82 and CD63 bands in a given tumor tissue sample were divided by the corresponding value of GAPDH, and the ratio was referred to as the gene expression ratio for each gene. The evaluated value of a specimen between 0%- 20% was defined as “Negative”; 20%-50% “Decreased”; 50-75% “Moderate”; 75% and more “Positive”.

Immunohistochemistry

Immunohistochemistry was performed by using Dako Coverplates (Dako, Germany) on frozen tissue sections of 6µm thickness. After 20min fixation in a 1:4 mixture of 3% H₂O₂ in ice cold 90% Methanol, the slides were washed in phosphate-buffered saline (PBS) and pre-incubated for 10min at room temperature with PBS – 1% bovine serum albumin (BSA), which was also used as a diluent for the antibodies. Successive sections were incubated overnight at 4° C with the CD9 (mouse monoclonal, MEM-61, abcam] at the dilutions of 1:200, the antibody against human CD82 (mouse monoclonal, clone 50F11, BD Pharmingen) at the dilutions of 1:300 and the antibody against human CD63 (mouse monoclonal, NKI/C3, Novocastra Laboratories Ltd) at the dilutions of 1:200, respectively. Negative control sections were only exposed to the secondary antibody and processed as described above. After 3x 10 min washes in PBS, sections were incubated for 30 min with a 1:1000 dilution of biotinylated goat anti-mouse secondary antibody (Dako-anti-IgG-Kit) followed by incubation with an avidin–biotin-peroxidase complex. Specific immunostaining was visualized with a 15% diaminobenzidine (DAB) chromogenic solution (Dako, Aarhus, Denmark). Finally, sections were lightly counterstained with Mayer’s hematoxylin. Tissue sections from a normal human tonsil (from patient who underwent tonsilectomy) were used as positive controls.

Interpretation of immunostaining scoring

We employed the planimetric measurement features by using the “PALM RoboSoftware 3.2” (PALM MicroLaser Systems) software to determine the immunostaining intensity. This software allows the user to encircle areas for calculation (µm²). The sum of all immunopositive cell squares (µm²) was calculated and compared with the total section area. Subjective interpretation of immunohistochemistry was minimized by using a modification of the German immunoreactive score (IRS) method (Table 2). The immunohistochemical scoring was performed by two independent reviewers. A consensus opinion was used to score the rare cases for divergent opinions. We assigned an intensity score (0 to 3+) and a distribution score (estimated percentage of reactive cells) to describe

staining of study cases. The criteria for scoring staining intensity were listed in table 2: To calculate the IRS, we assigned the following points for staining distribution: 1, 1-25% of cells; 2, 26-50%; 3, 51-75%; and 4, 76-100%. These points were then multiplied by the staining intensity score to give a range of potential IRSs from 0-12. Weak staining was defined as an IRS that ranged from 1 to 3, and moderate/ strong staining was 4-12.

Statistical analysis

Sigmaplot 8.0 was applied for all graphs calculations. Comparisons of the distributions of three TM4SF members expression for different groups were performed using the Wilcoxon–Mann–Whitney test (for two groups) or the Kruskal–Wallis test (for more than two groups). P-values of < 0.05 were considered to indicate statistical significance.

RESULTS

CD9, CD82 and CD63 gene expression in gastric cancer tissues analyzed by RT-PCR

All normal gastric epithelium and gastric ulcer tissues strongly expressed transcripts of CD9, CD63 and CD82. Out of 49 gastric cancers tissues investigated, 17 carcinomas (34.7%) were evaluated as CD9 positive and 32 carcinomas (65.3%) as CD9 negative. Furthermore, 17 carcinoma tissues (34.7%) were evaluated as CD82 positive and 32 carcinomas (65.3%) as CD82 negative. Only 6 carcinomas (12.2%) were evaluated as CD63 negative, but 43 carcinomas (87.8%) were CD63 positive (Figure 1).

CD9, CD82 and CD63 protein expression analyzed by immunohistochemistry

All normal gastric epithelium and gastric ulcer tissues were strongly expressed immunostaining of CD9, CD63 and CD82. Out of 49 gastric cancer tissues were studied by employing immunohistochemistry, 18 cases (36.7%) were classified as CD9 positive. In these cases, immunostaining of CD9 was intense and uniform on the cell-surface membrane (Figure 2). 31 cases (63.3%) revealed decreased CD9 expression, and the immunostaining in most of these tumors was heterogeneous. The immunohistochemical results were agreed with those of RT-PCR and 98.0% of the specimens coincided directly.

Further investigations demonstrated 21 CD82 positive cases (42.9%) and 27 CD82 negative cases (55.1%) (Figure 2). These results correlated with those of RT-PCR and 91.8% of the specimens coincided directly.

We identified 30 cases (61.2%) positive for CD63 and 19 CD63 negative cases (38.8%) (Figure 2). These results correlated with those of RT-PCR. However, only 73.5% of the specimens coincided directly.

Relationship between CD9, CD82 and CD63 gene expression and various prognostic factors

The relationship between CD9, CD63 and CD82 gene expression and various prognostic factors are shown in table 1. Analysis of CD9, revealed no statistically significant correlations between gene expression and age, gender, tumor status, differentiation, pTNM stage and Lauren classification. Contrary, CD9 protein level was associated with lymph node status ($p=0.03$) as well as with metastatic status ($p=0.013$); Compared with 7(63.6%) of N1 stage patients and 11(68.8%) of N2-3 stage patients, no N0 stage patients showed negative gene expression. Furthermore, only 4(36.3%) of M0 stage patients had negative gene expression compared with 13(72.2%) of M1 stage patients.

The relationship between CD63 and various prognostic factors were associated with gender ($p=0.09$) and nodal status ($p=0.028$). Six male patients (20.7%) showed negative gene expression, and 13 female patients (65%) were CD63 negative. Furthermore, only one (25%) patients with N0 and 3 (27.3%) patients with N1 demonstrated negative gene expression compared with 9 (69.2%) of N2-3 stage patients.

In contrast, CD82 protein level was associated with tumor status ($p=0.033$); metastatic status ($p=0$) and pTNM stage ($p=0.001$). 5 T1 patients(38.5%) were CD63 negative as compared with 6 T2 (54.5%) and 8 T3 (53.3%) patients. Analysis of metastatic status revealed that only 1 M0 patient (9%) and all M1 patients were CD63 negative. With respect to pTNM stage, only 2 stage I and II patients (22.2%) and no stage III patients were CD63 negative as compared with 10 stage IV (100%) patients.

DISCUSSION

In the present study, we investigated the expression of the three TM4SF members, CD9, CD63, and CD82. We demonstrated that CD9 protein levels were inversely associated with lymph node metastasis of gastric carcinoma. Furthermore, the reduction of CD9 protein was associated with distant metastasis of gastric cancer. Our results suggest that decreased levels of CD9 are strongly associated with an increased risk of recurrence, especially in patients with N0 nodal status and M0 metastatic status. These findings are consistent with previous reports demonstrating that reduced levels of CD9 correlated with poor prognosis of patients with breast and non-small cell lung cancers [13,27].

CD63 was originally described as a marker in the early stages of melanoma progression since it was highly expressed in radial growth-phase primary melanomas[28]. And it had been reported that it was strongly expressed on the cell surface in the early stage of malignant melanoma but weakens in the more advanced stages[25]. There is still no report showing that it is associated with other type of cancer. We demonstrated for the first time that mRNA levels of CD63 were associated with distant metastasis and CD63 protein correlated lymph node status. Taken together, these results suggested that decreased levels of CD63 were associated with a high pTNM staging and CD63 may served as a marker for metastatic potential of gastric cancer. Additionally, we found that CD63 proteins levels were lower in female that in male group. However, the reasons for that are still unclear and require further investigations.

CD82 has been identified as a metastasis suppressor gene[29]. Although the precise mechanisms for regulation of CD82 remain unclear, down-regulation rather than mutation is the most common mechanism in the progression of many cancers[14, 17, 22, 30-33]. In our study, we demonstrated that the decreased levels of CD82 protein were strikingly associated with the tumor status and the distant metastasis. Furthermore, CD82 protein expression was inversely associated with the pTNM stages. These results were consistent with previous findings showing a direct correlation between reduction of CD82 gene expression and bad prognosis in patients with prostatic cancer and non-small cell lung cancer[3, 34].

The mechanism of TM4SF mediated inhibition of cancer invasion and metastasis remains unclear. Cell adhesion and cell migration play important roles in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remodeling, and inflammation. Because of the specific structure of TM4SF[13], the extracellular domains can mediate specific protein-protein interactions with laterally associated proteins and unknown ligands, where they modulate integrin-dependent cell adhesion activities. The association of TM4SF members with various integrins is well documented. These members have little, if any, effect on the binding of

integrins to their ligands or on integrin-mediated static cell adhesion to the extracellular matrix[35]. Instead, they regulate post-ligand binding events, including integrin-mediated adhesion strengthening, a process whereby cells become increasingly resistant to detachment from immobilized integrin ligands[36].

The participation of TM4SF members in metastatic ability, morphological alternations and increased motility of tumor cells is often integrin-dependent. Previous reports demonstrated that the effects of CD63 on motility were similar to those reported for CD9 and both proteins were reported to associate with $\beta 1$ and $\beta 3$ integrins and to be identical with motility-related protein[36]. And previous work has also shown that the TM4SF members affect process such as cell proliferation, apoptosis and tumor metastasis. Various members of TM4SF associate with signaling enzyme, including protein phosphatases, conventional PKCs and type II phosphatidylinositol 4-kinase. CD82, as a suppressor of tumor cell metastasis, have the clearest mechanisms of the three members. the mechanisms of CD82 inhibits cell motility and invasiveness may because it can active the FAK-Src-p130Cas-CRKII pathway during cell migration and lead to DOCK180-dependent activation of Rac1 membrane ruffling and directional cell migration, with the p130Cas-CRKII complex functioning as a key "molecular switch"[37]. The association of CD82 with EWI2, another molecular that suppresses cell ruffling and migration[38], could also potentially contribute to the suppressor function of CD82. And CD82 attenuated signaling by the epidermal growth factor receptor (EGFR), and the related receptor ERBB2, by diminishing lig- and-induced dimerization and endocytosis[39]. This provides another avenue for CD82-mediated inhibition of cell migration and invasion.

For further understanding of the potential role of TM4SF in metastasis, we can go on to collect information of follow-up, and analyze the relationship of CD9, CD63 and CD82 with the Days after surgery. And in the future, we can also establish a gastric cancer cell model overexpressing CD9, CD63 or CD82, by using a plasmid vector. Then we can use the MTT test and Motility test to clarify relationship between wild type and the CD9, CD63 or CD82 overexpressing cells in cell proliferation and cell motility.

The classification of gastric cancers according to CD9, CD63 and CD82 expression might be useful in identifying patients for whom intensive adjuvant therapy is warranted. It is conceivable that testing tumors for TM4SF expression, in combination with other molecular and biochemical assays, may improve the prognostic evaluation of gastric cancer patients, and enhance the clinician's ability to prospectively identify patients who will have early disease recurrence and who require adjuvant chemotherapy. Many researches have shown that CD82 signalling may powerfully influence the development of metastasis. Although a significant amount of work is still required to uncover the mechanisms of action and regulation of CD82 in metastasis suppression, recent observations suggest that this metastasis suppressor gene and other members of this group of genes, like CD9 and CD63 will be of tremendous interest to the drug discovery industry for the development of therapeutics

agents. It is conceivable that investigates the tumors for TM4SF expression, in combination with other molecules, may improve the prognostic evaluation of gastric cancer patients, and enhance the clinician's ability to prospectively identify patients who will develop early disease recurrence and who require adjuvant chemotherapy.

AUTHORS' CONTRIBUTIONS

The work presented here was carried out in collaboration between all authors. ZC and CH defined the research theme. ZC, CH, SG and BG designed methods and experiments, carried out the laboratory experiments, analyzed the data, interpreted the results and wrote the paper. HD, NL and GZ co-designed experiments, co-discussed analyses, interpretation, and presentation. All authors have contributed to, seen and approved the final manuscript.

ACKNOWLEDGMENTS

We thank Mrs. K. Hammje for excellent technical assistance in collecting patient samples and clinical data. Our deep thank to Mr. Dr. Carsten Sekulla for his helpful statistic analysis support. This study was financial supported in part by the DFG and Deutsche Krebshilfe.

Supportive foundations: This work was supported in part by the DFG and Deutsche Krebshilfe.

REFERENCES

1. Wright MD and Tomlinson MG: The ins and outs of the transmembrane 4 superfamily. *Immunol. Today* 15:588–594, 1994.
2. Ikeyama S, Koyama M, Yamaoko M, Sasada R and Miyake M: Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. *J Exp Med* 177:1231–1237, 1993.
3. Dong JT, Suzuki H, Pin SS, et al: Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. *Cancer Res* 56:4387–4390, 1996.
4. Radford KJ, Thorne RF and Hersey P: CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta1 integrins in human melanoma. *Biochem Biophys Res Commun* 222:13–18, 1996.
5. Maecker HT, Todd SC and Levy S: The tetraspanin superfamily: molecular facilitators. *FASEB J* 11(6):428-442, 1997.

6. Boucheix C and Rubinstein E: Tetraspanins. *Cell Mol Life Sci* 58(9):1189-1205, 2001.
7. Miller WJ, Gonzalez-Sarmiento R and Kersey JH: Immunoglobulin and T-cell receptor gene rearrangement in blast crisis of chronic myelocytic leukemia. *Exp Hematol* 16(10):884-888, 1988.
8. Berditchevski F: Complexes of tetraspanins with integrins: more than meets the eye. *J Cell Sci* 114:4143–4151, 2001.
9. Berditchevski F and Odintsova E: Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. *J Cell Biol* 146:477–492, 1999.
10. Gutierrez-Lopez MD, Ovalle S, Yanez-Mo M, et al : A functionally relevant conformational epitope on the CD9 tetraspanin depends on the association with activated h1 integrin. *J Biol Chem* 278:208–218, 2003.
11. Longo N, Yáñez-Mó M, Mittelbrunn M, de la Rosa G, Muñoz ML, Sánchez-Madrid F and Sánchez-Mateos P: Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. *Blood* 98:3717–3726, 2001.
12. Peñas PF, García-Díez A, Sánchez-Madrid F and Yáñez-Mó M : Tetraspanins are localized at motility-related structures and involved in normal human keratinocyte wound healing migration. *J Invest Dermatol* 114:1126–1135, 2000.
13. Higashiyama M, Taki T, Ieki Y, et al: Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. *Cancer Res* 55: 6040–6044, 1995.
14. Huang CI, Kohno N, Ogawa E, Adachi M, Taki T and Miyake M: Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. *Am J Pathol* 153: 973–983, 1998.
15. Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF and Akiyoshi T: Motility related protein 1 (MRP1/CD9) expression in colon cancer. *Clin Cancer Res* 4:1507–1510, 1998.
16. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. *Science* 268:884-886, 1995.
17. Guo X, Friess H, Graber HU, Kashiwagi M, Zimmermann A, Korc M and Büchler MW: KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastasis. *Cancer Res* 56:4876-4880, 1996.
18. Yu Y, Yang JL, Markovic B, Jackson P, Yardley G, Barrett J and Russell PJ: Loss of KAI1 messenger RNA in both high grade and invasive human bladder cancers. *Clin Cancer Res* 3:1045-1049, 1997.
19. Ow K, Delprado W, Fisher R, Barrett J, Yu Y, Jackson P and Russell PJ: Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. *J Pathol* 191: 39-47, 2000.

20. Yang X, Wei L, Tang C, Slack R, Montgomery E and Lippman M: KAI1 Protein Is Down-Regulated during the Progression of Human Breast Cancer. *Clin Cancer Res* 6:3424-3429, 2000.
21. Hashida H, Takabayashi A, Tokuhara T et al : Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82. *Int J Cancer* 97(4):518-525, 2002.
22. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW and Barrett JC: Loss of KAI1 expression in the progression of colorectal cancer. *Cancer Res* 59(22):5724-5731, 1999.
23. Uzawa K, Ono K, Suzuki H, et al: High Prevalence of Decreased Expression of KAI1 Metastasis Suppressor in Human Oral Carcinogenesis. *Clin Cancer Res* 8:828-835, 2002.
24. Radford KJ, Thorne RF and Hersey P: Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. *J Immunol* 158(7):3353-3358, 1997.
25. Radford KJ, Mallesch J and Hersey P: Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). *Int J Cancer* 62(5):631-635, 1995.
26. Chen Z, Mustafa T, Trojanowicz B, et al: CD82 and CD63 in thyroid cancer. *Int J Mol Med* 14(4):517-27, 2004.
27. Miyake M, Nakano K, Itoi SI, Koh T and Taki T: Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. *Cancer Res* 56:1244-1249, 1996.
28. Hotta. H, Ross. AH, Huebner. K, et al: Molecular cloning and characterization of an antigen associated with early stage of melanoma tumor progression. *Cancer Res* 48:2955-2962, 1988.
29. Liu WM and Zhang XA: KAI1/ CD82, a tumor metastasis suppressor. *Cancer lett* 240:183-194, 2006.
30. Friess H, Guo XZ, Berberat P, Graber HU, Zimmermann A, Korc M and Büchler MW: Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. *Int. J. Cancer* 79:349-355, 1998.
31. Su JS, Arima K, Hasegawa M, et al: Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma. *Int J Urol* 11:74-82, 2004.
32. Bouras T and Rauman AG: Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. *J Pathol* 188:382-388, 1999.
33. Maurer CA, Graber HU, Friess H, et al: Reduced expression of the metastasis suppressor gene KAI1 in advanced colon cancer and its metastases. *Surgery* 126: 869-880, 1999.
34. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M and Miyake M: Correlation of CD82 gene expression with good prognosis in patients with non-small cell lung cancer. *Cancer Re* 56:1751-1755, 1996.


35. Berditchevski F and Odintsova E: Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. *J. Cell Biol* 146:477–492, 1999.
36. Hemler ME: Tetraspanin functions and associated microdomains. *Nat Rev Mol Cell Biol* 6(10):801-11, 2005.
37. Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K and Yamada KM: Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. *J. Cell Bio* 146:386-403, 1999.
38. Kolesnikova TV, Stipp CS, Rao RM, Lane WS, Luscinskas FW, Hemler ME: EWI-2 modulates lymphocyte integrin $\alpha 4\beta 1$ functions. *Blood* 103:3013-3019, 2004.
39. Odintsova, E, Sugiura, T, Berditchevski, F: Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. *Curr Biol* 10:1009-1012, 2000.

Table 1: Relation between CD9, CD63 and CD82 expression and various prognostic factors


clinicopathological characteristics	No. of patients	CD9			CD63			CD82						
		transcript average	p-value	protein average	transcript average	p-value	protein average	transcript average	p-value	protein average				
Gender														
Male	29	83.10	0.707	3.11	112.56	0.238	0.616	87.90	0.009	4.40	80.47	0.66	3.19	0.54
Female	20	82.31		4.06	110.12					3.00			2.64	
Age														
≤65	20	81.10	0.867	3.78	113.94	0.477	0.842	83.12	0.323	4.14	80.47	0.884	3.32	0.551
>65	29	83.97		3.27	109.83			86.00		3.54			2.74	
Tumor stage														
T1 and T2	13	85.14		3.75	114.23			91.38		3.73			4.00	
T3	11	89.98	0.79	3.43	107.64	0.215	0.462	78.34	0.81	3.17	80.47	0.866	2.39	0.033
T4	15	81.97		2.17	101.82			87.85		3.54			1.81	
Nodal status														
N0	5	74.61		5.60	105.13			67.82		4.25			4.40	
N1	13	79.73	0.556	2.91	106.47	0.03	0.774	77.85	0.028	4.23	80.47	0.23	2.88	0.094
N2	15	94.81		(N2 and N3)2,571	111.05			109.72		2.77			2.33	
N3	3	86.71			114.77			64.94		6.00			1.67	
metastatic status														
M0	11	90.68	0.403	4.64	121.84	0.013	0.036	90.40	0.137	3.90	80.47	0.77	4.35	0
M1	18	85.46		2.17	100.24			95.17		3.19			1.23	
Differentiation														
G1 and G2	5	81.93		4.20	118.89			83.67		5.25			3.75	
G3	24	85.77	0.82	3.05	108.33	0.624	0.432	87.57	0.105	3.31	80.47	0.691	2.23	0.304
G4	8	86.09		3.50	114.50			71.39		3.67			3.10	
pTNM stage														
I and II	12	79.10		4.08	109.53			73.67		3.91			4.06	
III	7	105.38	0.379	3.88	112.67	0.209	0.897	106.32	0.482	2.67	80.47	0.418	3.88	0.001
IV	19	69.66		2.50	96.80			46.35		3.68			0.95	
Lauren's classification														
intestinal type	12	69.30	0.105	3.42	109.93	0.538	0.719	80.17	0.06	4.50	80.47	0.773	3.80	0.535
diffuse type	22	91.26		3.03	112.63			84.80		3.41			3.41	

Table 2: Immunohistochemical scoring

A: Staining intensity	B: Percentage of positive Tumor cells	C: score
0 = no staining	0 = 0% positive cells	A x B = C
1 = weak staining	1 = < 10% positive cells	
2 = moderate staining	2 = 10 - 50% positive cells	
3 = strong staining	3 = 51 - 80% positive cells	
	4 = > 80% positive cells	



+ positive control; No.1-13: gastric carcinoma tissue samples



A,B,C: CD9, CD63 and CD82 expression in normal gastric mucosa; D,E,F: CD9, CD63 and CD82 expression in Gastric tumor tissue (non-metastasized); G,H,I: CD9, CD63 and CD82 expression Gastric tumor tissue (metastasized); J,K,L: CD9, CD63 and CD82 expression in Lymph node tissue (submucosa layer)